191 related articles for article (PubMed ID: 26070840)
1. Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.
Gufford BT; Chen G; Vergara AG; Lazarus P; Oberlies NH; Paine MF
Drug Metab Dispos; 2015 Sep; 43(9):1353-9. PubMed ID: 26070840
[TBL] [Abstract][Full Text] [Related]
2. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.
Kemp DC; Fan PW; Stevens JC
Drug Metab Dispos; 2002 Jun; 30(6):694-700. PubMed ID: 12019197
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
[TBL] [Abstract][Full Text] [Related]
4. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
Mizuma T
Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
[TBL] [Abstract][Full Text] [Related]
5. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
[TBL] [Abstract][Full Text] [Related]
6. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
Albassam AA; Frye RF; Markowitz JS
Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
[TBL] [Abstract][Full Text] [Related]
7. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.
Brantley SJ; Graf TN; Oberlies NH; Paine MF
Drug Metab Dispos; 2013 Sep; 41(9):1662-70. PubMed ID: 23801821
[TBL] [Abstract][Full Text] [Related]
8. Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.
Gufford BT; Chen G; Lazarus P; Graf TN; Oberlies NH; Paine MF
Drug Metab Dispos; 2014 Oct; 42(10):1675-83. PubMed ID: 25008344
[TBL] [Abstract][Full Text] [Related]
9. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
[TBL] [Abstract][Full Text] [Related]
10. Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.
Sun D; Jones NR; Manni A; Lazarus P
Cancer Prev Res (Phila); 2013 Jul; 6(7):719-30. PubMed ID: 23682072
[TBL] [Abstract][Full Text] [Related]
11. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases.
Jančová P; Siller M; Anzenbacherová E; Křen V; Anzenbacher P; Simánek V
Xenobiotica; 2011 Sep; 41(9):743-51. PubMed ID: 21524189
[TBL] [Abstract][Full Text] [Related]
12. Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.
Gufford BT; Graf TN; Paguigan ND; Oberlies NH; Paine MF
Drug Metab Dispos; 2015 Nov; 43(11):1734-43. PubMed ID: 26316643
[TBL] [Abstract][Full Text] [Related]
13. Identification of UDP-glucuronosyltransferases involved in the metabolism of silymarin flavonolignans.
Vrba J; Papoušková B; Lněničková K; Kosina P; Křen V; Ulrichová J
J Pharm Biomed Anal; 2020 Jan; 178():112972. PubMed ID: 31727359
[TBL] [Abstract][Full Text] [Related]
14. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
Ramírez J; Mirkov S; House LK; Ratain MJ
Drug Metab Dispos; 2015 Jul; 43(7):928-35. PubMed ID: 25870101
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of inhibitors of intestinal UDP-glucuronosyltransferases 1A8 and 1A10 using raloxifene as a substrate in Caco-2 cells: Studies with four flavonoids of Scutellaria baicalensis.
Chang CF; Chang YC; Lin JT; Yu CW; Kao YT
Toxicol In Vitro; 2021 Apr; 72():105087. PubMed ID: 33440186
[TBL] [Abstract][Full Text] [Related]
16. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism.
Trdan Lusin T; Trontelj J; Mrhar A
Drug Metab Dispos; 2011 Dec; 39(12):2347-54. PubMed ID: 21937736
[TBL] [Abstract][Full Text] [Related]
18. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.
Dalvie D; Kang P; Zientek M; Xiang C; Zhou S; Obach RS
Chem Res Toxicol; 2008 Dec; 21(12):2260-71. PubMed ID: 19548350
[TBL] [Abstract][Full Text] [Related]
19. Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (
Tian DD; Kellogg JJ; Okut N; Oberlies NH; Cech NB; Shen DD; McCune JS; Paine MF
Drug Metab Dispos; 2018 May; 46(5):552-560. PubMed ID: 29467215
[TBL] [Abstract][Full Text] [Related]
20. Absorption and metabolism of milk thistle flavanolignans in humans.
Calani L; Brighenti F; Bruni R; Del Rio D
Phytomedicine; 2012 Dec; 20(1):40-6. PubMed ID: 23072776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
